BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Foundation Fighting Blindness Grants RetroSense Therapeutics $250,000 for Research into Using Genes from Algae to Reverse Severe Vision Loss


2/10/2012 2:03:54 PM

Columbia, MD (February 10, 2012) – The Foundation Fighting Blindness, a national nonprofit dedicated to driving research for retinal degenerative diseases, announces a $250,000 research grant to Ann Arbor, Mich.-based RetroSense Therapeutics for developing a treatment that delivers the genes of blue-green algae to the retina for restoring vision. The funding supports RetroSense’s lab research in preparation for a clinical trial of the gene therapy in two to four years.

“Imagine if the secret to reversing blindness lies in the DNA of pond scum,” says Stephen Rose, Ph.D., chief research officer, Foundation Fighting Blindness. “This field of research, known as optogenetics, is a very promising and creative approach to restoring sight in people with severe vision loss or complete blindness due to inherited retinal diseases. RetroSense has outstanding technology, and it has achieved impressive results in lab studies. We are pleased to support the company in its effort to move the treatment into a clinical trial.”

In initial pre-clinical work, RetroSense has demonstrated that its treatment restores vision in mice with highly degenerated retinas. The current funding will help advance the initial studies toward a stage where the company could seek authorization for a Phase I clinical trial to confirm the therapy’s safety. The genetic treatment is delivered to retinal ganglion cells, which survive long after rods and cones, the cells that normally provide vision, are lost to advanced retinal degenerations like retinitis pigmentosa (RP). The treatment contains copies of an algal gene called channelrhodospin-2, which makes the ganglion cells light-sensitive. Normally, ganglion cells don’t provide vision; rather they help fine-tune the visual information generated by rods and cones.

“One big advantage of optogenetic treatments, including RetroSense’s, is that, because they are independent of the genetic defects causing disease, they will likely work for a variety of retinal degenerations,” says Dr. Rose. “It is exciting to support a therapeutic approach that has the potential to benefit many people.”

The company’s gene therapy uses an adeno-associated virus, or AAV, for delivering the therapeutic gene to the cells of the retina. The technology has performed well thus far in vision-restoring clinical trials of gene therapy for people with Leber congenital amaurosis. More than 40 people have been successfully treated in those studies.

The Foundation is also funding an optogenetic therapy project to revive cone cells — the cells in the retina that provide color and central vision. That effort is being led by Dr. José-Alain Sahel, director of the Foundation-funded Paris Research Center for the Study of Retina Degenerative Diseases, and Dr. Botond Roska of the Friedrich Miescher Institute for Biomedical Research in Switzerland.

About the Foundation Fighting Blindness

The Foundation Fighting Blindness is a national nonprofit driving research that will lead to preventions, treatments and cures for retinitis pigmentosa, macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases that affect more 10 million Americans. In its 40-year history, the Foundation has raised more than $450 million as the leading non-governmental funder of retinal research. Breakthrough Foundation-funded studies using gene therapy have restored significant vision in children and young adults who were previously blind, paving the way for using this method to treat a wide variety of retinal degenerative diseases, and proving a cure is in sight. With a network of nearly 50 chapters, the Foundation also provides support and resources to affected individuals and their families in communities across the country.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->